Bio-Rad Laboratories (Bio-Rad Laboratories) FCF Margin %

: 5.70% (As of Dec. 2023)

View and export this data going back to 1999. Start your Free Trial

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Bio-Rad Laboratories's Free Cash Flow for the three months ended in Dec. 2023 was $39 Mil. Bio-Rad Laboratories's Revenue for the three months ended in Dec. 2023 was $681 Mil. Therefore, Bio-Rad Laboratories's FCF Margin % for the quarter that ended in Dec. 2023 was 5.70%.

As of today, Bio-Rad Laboratories's current FCF Yield % is 2.73%.

The historical rank and industry rank for Bio-Rad Laboratories's FCF Margin % or its related term are showing as below:

BIO.B' s FCF Margin % Range Over the Past 10 Years
Min: -0.51 Med: 6.55 Max: 18.71
Current: 8.17

During the past 13 years, the highest FCF Margin % of Bio-Rad Laboratories was 18.71%. The lowest was -0.51%. And the median was 6.55%.

BIO.B's FCF Margin % is ranked better than
76.21% of 824 companies
in the Medical Devices & Instruments industry
Industry Median: -7.19 vs BIO.B: 8.17

Bio-Rad Laboratories FCF Margin % Historical Data

The historical data trend for Bio-Rad Laboratories's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bio-Rad Laboratories Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

15.55

18.71

18.33

2.87

8.17

Bio-Rad Laboratories Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
FCF Margin %																5.95	9.22	9.31	8.49	5.70

Competitive Comparison

For the Medical Devices subindustry, Bio-Rad Laboratories's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bio-Rad Laboratories FCF Margin % Distribution

For the Medical Devices & Instruments industry and Healthcare sector, Bio-Rad Laboratories's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Bio-Rad Laboratories's FCF Margin % falls into.

Bio-Rad Laboratories FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Bio-Rad Laboratories's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	218.263	/	2671.262
	=	8.17 %

Bio-Rad Laboratories's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	38.802	/	681.184
	=	5.70 %

Bio-Rad Laboratories FCF Margin % Related Terms

Thank you for viewing the detailed overview of Bio-Rad Laboratories's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Bio-Rad Laboratories (Bio-Rad Laboratories) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Bio-Rad Laboratories Inc (NYSE:BIO.B) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

BIO:USA BUWA:Germany

Address

1000 Alfred Nobel Drive, Hercules, CA, USA, 94547

Website

https://www.bio-rad.com

Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas, Europe and Africa , and Asia-Pacific. Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.